ZANATTA, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.005
AS - Asia 4.981
EU - Europa 2.451
SA - Sud America 878
AF - Africa 715
Continente sconosciuto - Info sul continente non disponibili 209
OC - Oceania 73
Totale 16.312
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.488
SG - Singapore 1.532
IT - Italia 874
VN - Vietnam 871
CN - Cina 782
BR - Brasile 558
HK - Hong Kong 473
BD - Bangladesh 234
DE - Germania 209
FR - Francia 161
IN - India 138
FI - Finlandia 129
CA - Canada 127
GB - Regno Unito 110
NL - Olanda 105
PL - Polonia 94
IQ - Iraq 84
TR - Turchia 79
AR - Argentina 77
JP - Giappone 76
RU - Federazione Russa 76
SE - Svezia 70
ES - Italia 51
EC - Ecuador 48
PH - Filippine 48
AT - Austria 47
CO - Colombia 47
ZA - Sudafrica 47
MX - Messico 44
ID - Indonesia 43
SA - Arabia Saudita 43
PK - Pakistan 42
KR - Corea 38
IE - Irlanda 37
UZ - Uzbekistan 35
BJ - Benin 34
DO - Repubblica Dominicana 33
JM - Giamaica 32
BG - Bulgaria 31
AZ - Azerbaigian 30
PY - Paraguay 30
KE - Kenya 29
AE - Emirati Arabi Uniti 28
BE - Belgio 28
MA - Marocco 28
MY - Malesia 28
EG - Egitto 27
KH - Cambogia 26
PS - Palestinian Territory 26
SO - Somalia 26
UA - Ucraina 26
NI - Nicaragua 25
CL - Cile 24
GR - Grecia 24
GT - Guatemala 24
IR - Iran 24
AM - Armenia 23
CH - Svizzera 23
HN - Honduras 23
IL - Israele 23
LU - Lussemburgo 23
PA - Panama 23
TN - Tunisia 23
TT - Trinidad e Tobago 23
VE - Venezuela 23
AL - Albania 22
JO - Giordania 22
LB - Libano 22
CZ - Repubblica Ceca 21
GA - Gabon 21
KG - Kirghizistan 21
ME - Montenegro 21
RO - Romania 21
RW - Ruanda 20
SN - Senegal 20
TH - Thailandia 20
UG - Uganda 20
UY - Uruguay 20
AU - Australia 19
CR - Costa Rica 19
DZ - Algeria 19
ET - Etiopia 19
HU - Ungheria 19
MK - Macedonia 19
NO - Norvegia 19
BS - Bahamas 18
PE - Perù 18
BA - Bosnia-Erzegovina 17
CM - Camerun 17
LY - Libia 17
MG - Madagascar 17
NP - Nepal 17
TZ - Tanzania 17
AO - Angola 16
BF - Burkina Faso 16
BO - Bolivia 16
BW - Botswana 16
CV - Capo Verde 16
HR - Croazia 16
ML - Mali 16
Totale 15.361
Salva come PNG Salva come JPEG
Città #
San Jose 999
Singapore 954
Ashburn 907
Hong Kong 424
Fairfield 405
Chandler 282
Ho Chi Minh City 272
Santa Clara 265
Hanoi 228
Council Bluffs 215
Los Angeles 189
Woodbridge 175
Houston 160
Beijing 140
Cambridge 139
Seattle 131
New York 123
Wilmington 107
Ann Arbor 105
Boardman 105
Chicago 103
Munich 96
Milan 84
Padova 81
Lauterbourg 74
Helsinki 70
Rome 65
Dallas 62
San Diego 59
Buffalo 58
São Paulo 57
Salt Lake City 53
Hefei 51
Da Nang 50
Bytom 47
Phoenix 46
Haiphong 43
Tokyo 42
Orem 41
Baghdad 39
Padua 39
Montreal 36
Brooklyn 35
Medford 35
Princeton 35
Stockholm 33
Cotonou 32
Denver 30
Dublin 30
Rio de Janeiro 30
San Francisco 30
Tashkent 30
Atlanta 29
Des Moines 29
London 29
Baku 28
Turku 28
Warsaw 28
Amsterdam 26
Bologna 25
Johannesburg 25
Nairobi 25
Naples 25
Tampa 25
Istanbul 24
Managua 24
Phnom Penh 24
Nuremberg 23
Elk Grove Village 22
Frankfurt am Main 22
Yerevan 22
Amman 21
Jeddah 21
Seoul 21
Sofia 21
Vienna 21
Athens 20
Kampala 20
Kingston 20
Bishkek 19
Dakar 19
Libreville 19
Panama City 19
Kigali 18
Montevideo 18
San José 18
Bến Tre 17
Manchester 17
Toronto 17
Addis Ababa 16
Antananarivo 16
Bengaluru 16
Nassau 16
Podgorica 16
Turin 16
Castries 15
Hargeisa 15
Hải Dương 15
Lappeenranta 15
Luxembourg 15
Totale 8.941
Salva come PNG Salva come JPEG
Nome #
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives 377
Cocaine- and Levamisole-Induced Vasculitis: Defining the Spectrum of Autoimmune Manifestations 320
Anti-MDA5 dermatomyositis: an update from bench to bedside 285
The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review 285
Therapy of scleroderma renal crisis: State of the art 282
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 282
Belimumab: a step forward in the treatment of systemic lupus erythematosus 269
Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment 268
Evaluation of right ventricular function performed by 3d-echocardiography in scleroderma patients 267
Alcoholic Etiology, Severity of Liver Disease, and Post-Transplant Adherence Are Correlated with Worse Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Liver Transplant Candidates 266
Balneotherapy in chronic inflammatory rheumatic diseases—a narrative review 259
Mud-bath treatment of seronegative spondyloarthritis: experience at the Euganean Thermal Area 251
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 246
Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis 245
The power of the EUSTAR cohort: key findings to date and implicationsfor management of systemic sclerosis patients 239
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database 238
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 237
Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: A newsworthy association 237
Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology 234
Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus 234
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort 231
Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases 230
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 229
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsets 224
Long-term improvement in activities of daily living in women with systemic sclerosis attending to occupational therapy. 224
Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis 221
Size-Exclusion Chromatography Combined with Ultrafiltration Efficiently Isolates Extracellular Vesicles from Human Blood Samples in Health and Disease 216
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 215
IL-12 and IL-23/Th17 axis in systemic lupus erythematosus 205
PD-1 gene rs2227981 (PD-1.5) polymorphism analysis in patients with systemic sclerosis 204
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 202
How I treat patients with systemic sclerosis in clinical practice 201
Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis 195
Correction to: Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. 189
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 188
Skin ulcers in systemic sclerosis: correlation with clinical phenotype in a monocentric cohort from the north-east of Italy 187
Higher Ventricular-Arterial Coupling Derived from Three-Dimensional Echocardiography Is Associated with a Worse Clinical Outcome in Systemic Sclerosis 186
Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. 185
Covid-19 and rheumatic autoimmune systemic diseases: Role of pre-existing lung involvement and ongoing treatments 183
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research 180
Prevalence of diaphragm dysfunction in patients with interstitial lung disease (ILD): The role of diaphragmatic ultrasound 174
Evaluation of extracellular vesicles as potential biomarkers of myositis 169
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 167
Coronary microvascular dysfunction in autoimmune rheumatic diseases: beyond coronary flow velocity reserve 166
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 156
Urinary incontinence in systemic sclerosis: a prospective multicentre cohort study 155
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort 153
Primordial and primary prevention in rheumatological diseases: The time has come 152
The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis 151
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS) 151
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? 150
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database 150
Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres 149
Update on Rheumatic Diseases in Clinical Practice 148
NITRIC OXIDE DIFFUSION IN PATIENTS WITH SSc 141
Does body composition matter in patients with systemic sclerosis? 140
The role of plasma exchange in the management of autoimmune disorders 140
Effects of mud-bath applications on synovial inflammation evaluated by contrasted-enhanced ultrasound (CEUS) in patients with psoriatic arthritis 140
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 139
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort 139
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 137
Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review 136
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 133
Systemic sclerosis sine scleroderma in children 131
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 130
Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension 125
Systemic sclerosis sine scleroderma is more aggressive in children than in adults 124
Human epididymis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathies 123
Hypovitaminosis D in an hospitalized old population of Western Friuli 118
Milk of calcium in scleromyositis 115
Systemic sclerosis: Recent insight in clinical management 114
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual 113
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort 112
Capillary Desertification and Refractory Digital Ulcers in Systemic Sclerosis 112
Should we use nintedanib as early therapy in patients with SSc-ILD? 111
Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR) 110
Scleroderma renal crisis: Case reports and update on critical issues 108
The Challenge of Diagnosing and Managing Pulmonary Arterial Hypertension in Systemic Sclerosis with Interstitial Lung Disease 107
Predictors of Persistent Disease Activity and Damage in Systemic Sclerosis: Associations With Mortality in a Single-Center Cohort Study 105
Prevalence and death rate of COVID-19 in systemic autoimmune diseases in the first three pandemic waves. Relationship to disease subgroups and ongoing therapies 97
Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat? 90
Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study 89
Systemic sclerosis: state of the art on clinical practice guidelines 86
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review 84
The Influence of Dietary Intervention in Connective Tissue Diseases: Evidence from Randomized Clinical Trials 80
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort 79
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma 76
Nailfold videocapillaroscopy in the assessment of juvenile connective tissue diseases 75
Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort 66
Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report 52
Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry 50
Patients with anti-SAE+ dermatomyositis display refractory and difficult-to-treat skin manifestations: case series from two Italian cohorts and review of literature 48
Efficacy of anifrolumab on skin, joint and lung involvement in anti-MDA5 positive dermatomyositis: a case report 46
Gastrointestinal involvement in very early and established systemic sclerosis: Insights from the SPRING-SIR national Italian registry 43
Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort 41
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 39
Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: A systematic literature review and meta-analysis 39
Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR study 39
Elderly-onset systemic sclerosis defines a distinct clinical subset: analysis from the SPRING registry of the Italian Society for Rheumatology 37
Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR) 37
Totale 16.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.102
article - articoli 47.251
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.353
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022490 0 35 50 29 13 70 40 41 25 40 37 110
2022/2023556 88 55 18 82 78 72 7 35 65 19 20 17
2023/2024568 21 57 66 51 50 64 42 27 35 30 57 68
2024/20252.219 30 170 89 118 213 95 185 183 126 101 383 526
2025/202610.212 506 659 1.160 1.499 960 436 1.340 779 1.211 695 481 486
2026/20271.052 612 440 0 0 0 0 0 0 0 0 0 0
Totale 16.312